Meningococcal Hexavalent Combination Vaccine

Techinvention Lifecare Private Limited
Granted App No 202421033292 Patent 573260 Bio Chemistry

Patent information

IP India · live record
Application number
202421033292
Filing date
26 April 2024
Status
Granted
Legal status
Inforce
Publication number
11/2025
Publication type
INA
Invention field
Bio Chemistry
Patent number
573260
Grant date
04 November 2025
Next renewal due
26 April 2026Overdue

Abstract

MENINGOCOCCAL HEXAVALENT COMBINATION VACCINE The present invention relates to biopharmaceuticals. The present invention relates to combination vaccine comprising hexavalent serogroup of Neisseria meningitidis for prevention and prophylaxis of infection caused by meningococcal bacteria. The present invention relates to a hexavalent combination vaccine comprising serogroups A, B, C, Y, W, X of Neisseria meningitidis. The present invention relates to a hexavalent combination vaccine comprising polysaccharide- protein conjugate of serogroups A, C, Y, W, X and proteins of serogroup B of Neisseria meningitidis. The present invention specifically relates to a hexavalent combination vaccine comprising polysaccharide- protein conjugate of serogroup A, C, Y, W, X and mutated Factor H binding proteins (fHbp) of serogroup B of Neisseria meningitidis. The present invention further relates to the composition, use and process of preparation of hexavalent combination vaccine.

Applicants

1
India
Techinvention Lifecare Private Limited 1004, THE SUMMIT BUSINESS PARK, OFF WEH METRO STATION, ANDHERI KURLA ROAD, ANDHERI EAST, MUMBAI 400093. INDIA

Inventors

4
India
SYED, S Ahmed1004, THE SUMMIT BUSINESS PARK, OFF WEH METRO STATION, ANDHERI KURLA ROAD, ANDHERI EAST, MUMBAI 400093. INDIA
India
SYED, Safia1004, THE SUMMIT BUSINESS PARK, OFF WEH METRO STATION, ANDHERI KURLA ROAD, ANDHERI EAST, MUMBAI 400093. INDIA
India
KUMAR, Varnik1004, THE SUMMIT BUSINESS PARK, OFF WEH METRO STATION, ANDHERI KURLA ROAD, ANDHERI EAST, MUMBAI 400093. INDIA
India
BHAGAWATI, Arnabjyoti1004, THE SUMMIT BUSINESS PARK, OFF WEH METRO STATION, ANDHERI KURLA ROAD, ANDHERI EAST, MUMBAI 400093. INDIA

Claims

4
1 A hexavalent combination vaccine comprising (a) a combination of polysaccharidecarrier protein glycoconjugates of serogroups A, C, Y, W, and X of Neisseria meningitidis; and (b) one or more proteins of serogroup B of N. meningitidis.
2 The hexavalent combination vaccine as claimed in claim 1, wherein the carrier protein selected from diphtheria toxoid, CRM197, tetanus toxoid, pertussis toxoid, E. coli LT, E. coli ST, and exotoxin A from Pseudomonas aeruginosa, Bacterial outer membrane proteins such as, outer membrane complex c (OMPC), porins, transferrin binding proteins, pneumolysis, pneumococcal surface protein A (PspA), or pneumococcal adhesin protein (PsaA).
3 The hexavalent combination vaccine as claimed in claim 1, wherein the carrier protein is individually conjugated to the polysaccharides of serogroups A, C, Y, W and X.
4 A method of preparing the polysaccharide-carrier protein glycoconjugates of serogroups A, C, Y, W, and X of Neisseria meningitidis as claimed in anyone of claims 1-3 comprises the steps of: a) cultivating meningitis serogroup strains A, C, Y, W and X in presence of complex media for about 12–20 hours to produce meningococcal A, C, Y, W, and X polysaccharides; b) purifying the meningococcal A, C, Y, W, and X polysaccharides by processes selected from ultrafiltration, cetyl-trimethylammonium bromide (CTAB) precipitation, centrifugation, depth filtration, ethanol, and salt precipitation; c) activating each of the purified meningococcal A, C, Y, W, and X polysaccharides at an alkaline pH of 8.5–9.5 in the presence of 1-Cyano -4 Dimethylaminopyridine Tetrafluoroborate (CDAP) and at a temperature ranging from 8-15 oC; d) activating or derivatizing the carrier protein by 1-ethyl-3-(dimethylaminopropyl)- carbodiimide (EDAC) for about 16–24 hours; e) mixing and conjugating the activated A, C, Y, W, and X polysaccharides and the activated carrier proteins to obtain the polysaccharide-carrier protein glycoco

Specification

Show full textCollapse

We Claim: 1. A hexavalent combination vaccine comprising (a) a combination of polysaccharidecarrier protein glycoconjugates of serogroups A, C, Y, W, and X of Neisseria meningitidis; and (b) one or more proteins of serogroup B of N. meningitidis. 2. The hexavalent combination vaccine as claimed in claim 1, wherein the carrier protein selected from diphtheria toxoid, CRM197, tetanus toxoid, pertussis toxoid, E. coli LT, E. coli ST, and exotoxin A from Pseudomonas aeruginosa, Bacterial outer membrane proteins such as, outer membrane complex c (OMPC), porins, transferrin binding proteins, pneumolysis, pneumococcal surface protein A (PspA), or pneumococcal adhesin protein (PsaA). 3. The hexavalent combination vaccine as claimed in claim 1, wherein the carrier protein is individually conjugated to the polysaccharides of serogroups A, C, Y, W and X. 4. A method of preparing the polysaccharide-carrier protein glycoconjugates of serogroups A, C, Y, W, and X of Neisseria meningitidis as claimed in anyone of claims 1-3 comprises the steps of: a) cultivating meningitis serogroup strains A, C, Y, W and X in presence of complex media for about 12–20 hours to produce meningococcal A, C, Y, W, and X polysaccharides; b) purifying the meningococcal A, C, Y, W, and X polysaccharides by processes selected from ultrafiltration, cetyl-trimethylammonium bromide (CTAB) precipitation, centrifugation, depth filtration, ethanol, and salt precipitation; c) activating each of the purified meningococcal A, C, Y, W, and X polysaccharides at an alkaline pH of 8.5–9.5 in the presence of 1-Cyano -4 Dimethylaminopyridine Tetrafluoroborate (CDAP) and at a temperature ranging from 8-15 oC; d) activating or derivatizing the carrier protein by 1-ethyl-3-(dimethylaminopropyl)-carbodiimide (EDAC) for about 16–24 hours; e) mixing and conjugating the activated A, C, Y, W, and X polysaccharides and the activated carrier proteins to obtain the polysaccharide-carrier protein glycoco

Documents

Sign in to open
Application documents
1 202421033292-STATEMENT OF UNDERTAKING (FORM 3) [26-04-2024(online)].pdf 26 Apr 2024
2 202421033292-PROVISIONAL SPECIFICATION [26-04-2024(online)].pdf 26 Apr 2024
3 202421033292-POWER OF AUTHORITY [26-04-2024(online)].pdf 26 Apr 2024
4 202421033292-FORM FOR SMALL ENTITY(FORM-28) [26-04-2024(online)].pdf 26 Apr 2024
5 202421033292-FORM 1 [26-04-2024(online)].pdf 26 Apr 2024
6 202421033292-EVIDENCE FOR REGISTRATION UNDER SSI(FORM-28) [26-04-2024(online)].pdf 26 Apr 2024
7 202421033292-DECLARATION OF INVENTORSHIP (FORM 5) [26-04-2024(online)].pdf 26 Apr 2024
8 202421033292-Power of Attorney [10-02-2025(online)].pdf 10 Feb 2025
9 202421033292-FORM28 [10-02-2025(online)].pdf 10 Feb 2025
10 202421033292-Form 1 (Submitted on date of filing) [10-02-2025(online)].pdf 10 Feb 2025
11 202421033292-Covering Letter [10-02-2025(online)].pdf 10 Feb 2025
12 202421033292-CERTIFIED COPIES TRANSMISSION TO IB [10-02-2025(online)].pdf 10 Feb 2025
14 202421033292-Sequence Listing in PDF [19-02-2025(online)].pdf 19 Feb 2025
15 202421033292-DRAWING [19-02-2025(online)].pdf 19 Feb 2025
16 202421033292-CORRESPONDENCE-OTHERS [19-02-2025(online)].pdf 19 Feb 2025
17 202421033292-COMPLETE SPECIFICATION [19-02-2025(online)].pdf 19 Feb 2025
18 202421033292-FORM-9 [26-02-2025(online)].pdf 26 Feb 2025
19 202421033292-MSME CERTIFICATE [01-03-2025(online)].pdf 01 Mar 2025
20 202421033292-FORM28 [01-03-2025(online)].pdf 01 Mar 2025
21 202421033292-FORM 18A [01-03-2025(online)].pdf 01 Mar 2025
22 202421033292-FER.pdf 18 Sep 2025
23 202421033292-OTHERS [28-10-2025(online)].pdf 28 Oct 2025
24 202421033292-FER_SER_REPLY [28-10-2025(online)].pdf 28 Oct 2025
25 202421033292-DRAWING [28-10-2025(online)].pdf 28 Oct 2025
26 202421033292-COMPLETE SPECIFICATION [28-10-2025(online)].pdf 28 Oct 2025
27 202421033292-CLAIMS [28-10-2025(online)].pdf 28 Oct 2025
28 202421033292-PatentCertificate04-11-2025.pdf 04 Nov 2025
29 202421033292-IntimationOfGrant04-11-2025.pdf 04 Nov 2025
30 202421033292-FORM 8A [07-11-2025(online)].pdf 07 Nov 2025
31 202421033292-FORM 8A [07-11-2025(online)]-1.pdf 07 Nov 2025
Search strategy
1202421033292_SearchStrategyNew_E_SEARCHE_16-09-2025.pdf

ERegister / renewals

Inforce

No renewals recorded.